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SUMMARY
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are age-related 
neurodegenerative disorders with shared genetic etiologies and overlapping clinical and 
pathological features. Here we studied a novel ALS/FTD family and identified the P362L 
mutation in the low complexity domain (LCD) of T-cell-restricted intracellular antigen-1 (TIA1). 
Subsequent genetic association analyses showed an increased burden of TIA1 LCD mutations in 
ALS patients compared to controls (P = 8.7×10−6). Postmortem neuropathology of five TIA1 
mutations carriers showed a consistent pathological signature with numerous round, hyaline, TAR 
DNA-binding protein 43 (TDP-43)-positive inclusions. TIA1 mutations significantly increased the 
propensity of TIA1 protein to undergo phase transition. In live cells, TIA1 mutations delayed 
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stress granule (SG) disassembly and promoted the accumulation of non-dynamic SGs that 
harbored TDP-43. Moreover, TDP-43 in SGs became less mobile and insoluble. The identification 
of TIA1 mutations in ALS/FTD reinforces the importance of RNA metabolism and SG dynamics 
in ALS/FTD pathogenesis.
Keywords
amyotrophic lateral sclerosis; frontotemporal dementia; T-cell-restricted intracellular antigen-1; 
stress granules; TDP-43
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, 
characterized by progressive degeneration of upper and lower motor neurons that ultimately 
leads to death by respiratory failure (Taylor et al., 2016a). While most patients present with 
ALS alone, a subset of individuals present with concomitant frontotemporal dementia (ALS/
FTD) (Hardy and Rogaeva, 2014). Recent gene discoveries and clinicopathological studies 
have highlighted that ALS and FTD are part of a disease continuum with a shared genetic 
etiology (Ji et al., 2017; Neumann et al., 2006). Repeat expansions in the chromosome 9 
open reading frame 72 gene (C9orf72) and mutations in TBK1 (encoding TANK-binding 
kinase 1), and TARDBP (encoding transactive response DNA-binding protein 43, TDP-43) 
are among the most common genetic causes of the combined ALS/FTD phenotype and, 
notably, each of these mutations results in pathology characterized by TDP-43-positive 
neuronal cytoplasmic inclusions (Cirulli et al., 2015; DeJesus-Hernandez et al., 2011; 
Freischmidt et al., 2015; Kabashi et al., 2008; Renton et al., 2011; Sreedharan et al., 2008). 
However, the cause of a significant number of ALS and ALS/FTD cases remains unknown.
Many ALS-causing mutations impact proteins involved in RNA metabolism, including 
RNA-binding proteins such as TDP-43, fused in sarcoma (FUS), and heterogeneous nuclear 
ribonucleoprotein A1 (hnRNPA1) (Taylor et al., 2016). These and related RNA-binding 
proteins are components of membrane-less organelles found in the nucleus (e.g., nuclear 
speckles and nucleoli) and cytoplasm (e.g., processing bodies and stress granules, SGs) of 
neurons and other cell types (Brangwynne et al., 2011; Collier et al., 1988; Huang and 
Spector, 1992; Sheth and Parker, 2003; Taylor et al., 2016b). It has recently emerged that 
biophysical properties encoded in prion-like, low complexity sequence domains (LCDs) of 
RNA-binding proteins promote the assembly of membrane-less organelles through the 
process of liquid-liquid phase separation (LLPS) (Kato et al., 2012; Lin et al., 2015; Molliex 
et al., 2015; Patel et al., 2015).
Here we report the identification of rare mutations impacting the LCD of the RNA-binding 
protein T-cell-restricted intracellular antigen-1 (TIA1) in ALS and ALS/FTD patients. TIA1 
is a prominent SG component and the LCD of TIA1 plays a central role in promoting SG 
assembly (Gilks et al., 2004; Kedersha et al., 2000; Panas et al., 2016). We found that 
disease-associated mutations alter biophysical properties of TIA1 by significantly increasing 
the propensity towards phase separation, delaying SG disassembly, and promoting the 
accumulation of non-dynamic SGs that harbor TDP-43. Moreover, TDP-43 recruited into 
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SGs becomes less mobile and insoluble. These findings reinforce the importance of 
disturbed RNA metabolism in ALS/FTD and place altered membrane-less organelle 
dynamics at the center of ALS/FTD pathogenesis.
RESULTS
Identification of TIA1 Mutations in Patients with ALS and ALS/FTD
We performed whole-exome sequencing in a pair of second-degree relatives with clinical 
features of both ALS and FTD, and with autopsy confirmed TDP-43 pathology. These 
individuals were from a multigenerational ALS/FTD family of European ancestry (UBCU2), 
negative for mutations in known ALS- and FTD-causing genes (Figure 1A). To identify 
candidate causal mutations, we filtered the genetic variants to those that were observed in 
the heterozygous state in both affected family members, altered the amino acid sequence, 
were absent from the Exome Variant Server population, and were present two or fewer times 
in the Exome Aggregation Consortium (ExAC) (Kobayashi et al., 2017). Among the 17 
genes with such variants (all confirmed by Sanger sequencing), 15 were expressed in brain 
and five had variants with a combined annotation dependent depletion (CADD) score > 20, 
indicating that they are among the 1% most deleterious variants in the genome (Table S1). 
Interestingly, one of these was a missense variant (P362L) in TIA1. Similar to the ALS-
related disease proteins TDP-43, hnRNPA1 and FUS, TIA1 is an RNA-binding protein 
containing a prion-like LCD and assembles into membrane-less organelles, including SGs 
(Taylor et al., 2016a). A different heterozygous founder mutation that affects the TIA1 LCD 
(E384K) was previously reported in Swedish/Finnish patients as the cause of Welander 
distal myopathy (WDM) (Brand et al., 2016; Hackman et al., 2013; Klar et al., 2013), a 
rimmed vacuolar myopathy characterized by aggregates of TDP-43 and p62. WDM is 
clinically similar to and shares histopathological features with myopathies caused by 
mutations in valosin containing protein (VCP), p62/SQSTM1, HNRNPA1, HNRNPA2B1 
and MATR3, disease genes that have also been associated with ALS/FTD (Fecto et al., 
2011; Johnson et al., 2010; Johnson et al., 2014; Kim et al., 2013). Moreover, the P362L 
mutation in TIA1 affects a highly conserved residue in the LCD (Figure 1B) and was 
predicted to be possibly damaging or deleterious by several in silico prediction algorithms 
(SIFT, PolyPhen, Mutation Taster). Together, these observations led us to prioritize TIA1 as 
an ALS/FTD candidate gene. To this end, we analyzed the TIA1 LCD (encoded by exons 
11–13) in a cohort of 1039 ALS or ALS/FTD patients and 3036 controls free of 
neurodegenerative diseases, and identified an increased burden of rare heterozygous TIA1 
mutations in patients compared to controls (P = 8.7×10−6, SKAT-O adjusted for age and 
sex). Specifically, in the association cohort we identified five additional TIA1 mutations in a 
total of six unrelated patients, whereas no mutations were detected in controls (Figure 1B; 
Table S2). All TIA1 mutations identified in patients had CADD scores > 20 (Table S2).
Clinical and Pathological Presentation of TIA1 Mutation Carriers
The nine affected TIA1 mutation carriers (three members of UBCU2 and six additional 
unrelated patients) had an average disease onset age of 58.9 ± 13.7 years, with most patients 
presenting in mid-to-late adult life, with the exception of patient UBCU2-14 who had an 
unusually early onset of FTD and ALS symptoms at 28 years. Patients typically presented 
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with either focal weakness or aphasia and all eventually developed ALS-type motor 
dysfunction, with accompanying features of FTD in five patients (Table S2). A positive 
family history of a similar neurodegenerative disease was documented in three of seven 
probands, resulting in a frequency of potential pathogenic TIA1 mutations in 2.2% of 
familial patients (3/136) and 0.4% of sporadic patients (4/903). Although all nine confirmed 
mutation carriers were female, there were affected males in some of the families. Autopsy 
material available for UBCU2-1, UBCU2-14 and three other unrelated patients (TOR-1, 
NWU-1, and ALS752-1) revealed TDP-43-immunoreactive pathology in the extra-motor 
neocortex (characteristic of FTLD-TDP type B), motor cortex and spinal cord, which 
correlated with the clinical diagnoses of FTD and ALS in these patients, and which fell 
within the broad spectrum of pathology that is typically encountered in other cases of 
familial and sporadic ALS/FTD (Figure 1C; Table S3; Figure S1). In addition, all five 
autopsy cases showed large, round, hyaline, Lewy body-like cytoplasmic inclusions in lower 
motor neurons, visible with hematoxylin and eosin staining (Figure 1Cii, Figure S1) and also 
with TDP-43 immunohistochemistry (Figure 1Ciii, Figure S1). Although similar hyaline 
Lewy body-like inclusions are occasionally seen in sporadic ALS patients, their frequency 
and consistent presence in the five TIA1 mutation carriers suggests that these could be a 
pathological signature of TIA1-related disease (Figure S1). Immunohistochemistry and 
double-label immunofluorescence using a panel of commercial antibodies raised against 
different TIA1 epitopes did not demonstrate any difference in staining between ALS/FTD 
patients with and without TIA1 mutations; specifically, there was no co-localization of TIA1 
with TDP-43 immunoreactive inclusions (Figure S1). Consistent with these immunostaining 
results, protein extracts from post mortem tissue of TIA1 mutation carriers did not show an 
obvious increase in TIA1 levels in the urea fraction as compared to protein extracts from 
non-TIA1 mutation carriers and controls (Figure S1).
Mutations Alter the Biophysical Properties of TIA1 to Promote LLPS
TIA1 is a prototypical hnRNP that contains three RNA recognition motifs (RRMs) and a C-
terminal LCD that is predicted to be intrinsically disordered (Figure 2A). LCDs in RNA-
binding proteins such as hnRNPA1, TDP-43, and FUS contribute to the assembly of liquid-
like membrane-less organelles such as SGs through the biophysical process of LLPS (Lin et 
al., 2015; Molliex et al., 2015; Murakami et al., 2015; Patel et al., 2015). Consistent with the 
behavior of these other RNA-binding proteins, the LCD (amino acids 290–386) of TIA1 has 
been shown to undergo LLPS in the presence of RNA (Lin et al., 2015). We found that full-
length TIA1 spontaneously phase separated at room temperature, in the absence of any co-
solute, at physiological ionic strength of 150 mM, and pH 7.5 (Figure 2B; Figures S2A and 
S2B). To examine the impact of disease-associated mutations on LLPS of TIA1, we 
expressed and purified two ALS-associated TIA1 mutants identified in this study (P362L 
and A381T) as well as the E384K mutant form associated with WDM (Figure 2A; Figure 
S2A and S2B) (Hackman et al., 2013; Klar et al., 2013). All three mutant proteins 
underwent spontaneous temperature- and concentration-dependent LLPS to create liquid 
droplets that at early time points were morphologically indistinguishable from liquid 
droplets formed by wild-type protein (Figure 2C). To quantify the propensity of each protein 
to undergo phase separation, we constructed a phase diagram by measuring the co-existence 
line of protein-depleted light phase and protein-enriched dense phase as a function of 
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temperature and protein concentration. The P362L, A381T, and E384K mutant proteins 
caused a significant leftward shift in the co-existence line to a lower protein concentration, 
indicating an increased propensity of mutant TIA1 to phase separate, due to stronger 
intermolecular protein-protein interactions (Figure 2C).
Upon phase separation, the RNA-binding proteins hnRNPA1, FUS, and TDP-43 can access 
a spectrum of assemblies that exhibit progressively increased order and decreased mobility, 
ranging from liquid droplet to hydrogel to amyloid-like fibril (Schmidt and Gorlich, 2016). 
Similar to observations in other RNA-binding proteins, we found that when TIA1 droplets 
were allowed to settle on a coverslip surface and observed over time, droplets of mutant 
forms of TIA1 converted to thioflavin T (ThT)-positive fibrils within the liquid droplets 
within 45 minutes, at which time the droplets dissipated (Figure S2C). Although droplets of 
wild-type TIA1 also converted to ThT-positive fibrillary material followed by droplet 
dissipation, this process occurred over a much longer time course (i.e., ≥ 24 hours). 
Transmission electron micrographs confirmed the formation of amyloid-like fibrils of wild-
type and mutant TIA1 (Figure S2D). Using a quantitative ThT fluorescence assay, we 
confirmed that disease-associated mutations in TIA1 significantly accelerated fibrillization 
of TIA1 (Figure S2E), similar to the consequence of disease-causing mutations in 
hnRNPA1, hnRNPA2B1, and FUS (Kim et al., 2013; Molliex et al., 2015; Patel et al., 2015). 
Although the importance of fibril formation in the normal physiological function of RNA-
binding proteins and in disease pathogenesis is currently not known, these results provide 
further evidence that disease-associated mutations alter biophysical properties of TIA1; 
specifically, strengthening intermolecular interactions of TIA1 assemblies.
We next used fluorescence recovery after photobleaching (FRAP) to measure the mobility of 
fluorescently tagged TIA1 (Matsuda and Nagai, 2014). We found that disease-associated 
mutations significantly altered the dynamic exchange of TIA1 between the dense droplet 
phase and the light mono-disperse phase, with increased half-recovery times and a smaller 
overall mobile fraction (Figure 2D, 2E, and 2F). These results suggest that the mutations 
changed the material properties of mutant TIA1 droplets by enhancing transient, nonspecific 
intermolecular interactions that reduce protein mobility. This observation raises the 
possibility that material properties of membrane-less organelles composed of TIA1 protein 
in live cells, such as SGs, could be adversely affected by the disease-associated mutations.
Mutations in TIA1 Impair Stress Granule Dynamics
TIA1 is a prominent SG component and the LCD of TIA1 plays a central role in promoting 
SG assembly (Gilks et al., 2004; Kedersha et al., 2000; Panas et al., 2016). To assess the 
impact of TIA1 mutations on SG dynamics, we established a live-cell assay that permits 
real-time monitoring of the kinetics of SG assembly and disassembly in response to a tightly 
controlled heat pulse. We used this system to monitor SG dynamics in HeLa cells expressing 
N-terminal GFP-tagged TIA1 wild-type, P362L, A381T, or E384K mutants (Video File). 
GFP-tagged TIA1 showed the identical subcellular distribution as endogenous or untagged 
TIA1 proteins, and the frequency and size of SGs containing these proteins were not altered 
by introduction of exogenous TIA1 at this modest expression level (Figure S3). We observed 
no significant impact of the P362L, A381T, or E384K TIA1 mutations on the rates of SG 
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assembly. By contrast, each of these disease-associated mutations resulted in significantly 
protracted SG disassembly, as assessed by both blinded manual counting and automated 
image analysis (Figure 3A and 3B; Figure S4A–D). The consequence of impaired SG 
disassembly in cells expressing mutant TIA1 was a significant accumulation of non-
dynamic, TDP-43-containing SGs that persisted for hours after SGs had disappeared from 
the cells expressing wild-type TIA1 (Figure 3C and 4A). This finding is consistent with a 
prior report that the E384K WDM-causing mutation is associated with increased numbers of 
SGs that show dynamics alterations as assessed by FRAP (Hackman et al., 2013).
TDP-43 Recruited to Stress Granules Becomes Insoluble
TIA1 mutation carriers with ALS/FTD exhibit prominent TDP-43 pathology (Figure 1C; 
Figure S1; Table S3). The impact of mutant TIA1 on SG dynamics and the abnormal 
accumulation of TDP-43-containing SGs prompted us to examine the relationship between 
SG dynamics and TDP-43 solubility. Upon stress, TDP-43 is recruited to TIA1-positive SGs 
(Figure 4A). To examine the consequence of TDP-43 being recruitment into SGs, we 
transfected cells with TdTomato-tagged TDP-43 and assessed mobility of this protein using 
FRAP. In resting cells, TdTomato-TDP-43 in the nucleus and cytoplasm exhibited rapid 
mobility (Figure 4B and 4C). However, upon stress, the TdTomato-TDP-43 that was 
recruited to SGs became almost completely immobile, whereas the cytoplasmic TdTomato-
TDP-43 that was not associated with SGs, in these same cells, remained mobile (Figure 4B 
and 4C). Biochemical assessment revealed a correlation between reduced mobility of 
TDP-43 upon recruitment to SGs and reduced TDP-43 solubility. Specifically, in resting 
cells TDP-43 was largely recovered in a detergent-soluble fraction (Figure 4D and 4E). In 
contrast, the TDP-43 derived from cells that had been stressed for 30 minutes, showed a 
significant shift from the detergent-soluble fraction to an insoluble pellet that was recovered 
by treatment with urea (Figure 4D and 4E). Notably, the solubility change that occurred 
under these conditions was reversible; three hours after recovery from the 30 minute stress, 
and coincident with the clearance of SGs, TDP-43 returned to the detergent-soluble fraction 
(Figure 4D and 4E). However, the reversibility of insoluble TDP-43 accumulation was 
influenced by the duration of stress. Upon doubling the duration of stress from 30 minutes to 
one hour, we found that TDP-43 became permanently insoluble and failed to return to the 
detergent-soluble fraction after 3 hours of recovery. Taken together, these observations 
suggest that persistent, poorly dynamic SGs could promote the conversion of TDP-43 from a 
soluble to a stable insoluble form.
DISCUSSION
Using exome sequencing in a novel FTD/ALS family, we identified the P362L mutation in 
the LCD of TIA1 as a strong causal candidate for disease. We subsequently identified five 
additional LCD TIA1 mutations in a total of six unrelated patients; whereas, none was found 
in controls free of neurodegenerative disease (p=8.7×10−6 in gene burden analysis). While 
the lack of mutations in our well-characterized control population suggests the TIA1 
mutations are causal ALS-FTD gene mutations (with an age-related disease penetrance), we 
acknowledge that the same TIA1 mutations identified in our ALS-FTD patients are reported 
at very low frequency in the ExAC database (minor allele frequency<0.0001) classifying 
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them as strong ALS-FTD risk factors instead. Using the European non-Finnish population 
from the ExAC database, an allele count of 26 is reported for rare TIA1 alleles in the LCD, 
which compared to the frequency in our ALS patients would result in a conservative odds 
ratio (OR) of 6.9 (confidence interval, CI: 2.5–16.5) for TIA1 allele carriers to develop ALS 
(p=0.00018). This is likely an underestimate which assumes that only 26,725 individuals in 
ExAC were sequenced for the entire gene, that all variants reported are real and observed in 
heterozygous state in independent individuals and that all carriers would be free of ALS. 
This estimate also includes variants observed in ExAC with CADD<20, whereas all 
mutations identified in our ALS patients had CADD>20. The OR for carriers of a rare TIA1 
variant in the LCD with CADD>20 to develop ALS would be 15.1 (CI: 5.0–41.7; 
p=3.4×10−6). While future studies in ALS-FTD patient cohorts and control populations will 
be critical to evaluate the specific contribution of TIA1 mutations to ALS-FTD it is 
important to note that even the E384K mutation, considered pathogenic in WDM, is 
observed seven times in ExAC. Additionally, it is highly plausible that, as-yet-unknown, 
genetic and environmental factors affect the disease penetrance of TIA1 mutations and that 
these factors may have contributed to the development of ALS/FTD in our patients. While 
speculative, the fact that all of our affected confirmed mutation carriers are females may 
suggest that these mutations are more penetrant in females than males; however, this also 
needs to be studied in additional cohorts. Importantly, detailed neuropathological analysis 
revealed strikingly uniform pathology with an unusually high frequency of hyaline Lewy 
body-like cytoplasmic inclusions in lower motor neurons in all five TIA1 mutation carriers 
with autopsy confirmation (with four different TIA1 mutations), further supporting a 
common pathomechanism in these patients. Overall, our findings suggest that TIA1 
mutations are a rare cause of ALS ± FTD, accounting for ~2% of familial ALS and < 0.5% 
of sporadic ALS; frequencies that are comparable to those for mutations in other ALS genes 
such as VCP and profilin1 (PFN1) (Johnson et al., 2010; Wu et al., 2012).
Mounting evidence indicates that altered dynamics of membrane-less organelles such as SGs 
contribute to age-related degenerative diseases, including the most common forms of ALS, 
FTD, myopathy, and possibly Alzheimer’s disease and other tauopathies (Aulas and Vande 
Velde, 2015; Brunello et al., 2016; Taylor et al., 2016a; Vanderweyde et al., 2016; 
Vanderweyde et al., 2012); although the precise molecular mechanism for this disturbance in 
some cases has been unclear. The LCDs of RNA-binding proteins promote the assembly of 
membrane-less organelles through the process of LLPS (Lin et al., 2015; Molliex et al., 
2015; Patel et al., 2015). Disease-causing mutations that impact the LCDs of several RNA-
binding proteins, including hnRNPA1, FUS, and TDP-43, strengthen intermolecular LCD 
interactions, as evidenced by an increased propensity of these proteins to assemble into 
amyloid-like fibrils under experimental conditions (Kim et al., 2013; Molliex et al., 2015; 
Patel et al., 2015), although an impact on phase separation and the material properties of the 
liquid phase has not been previously documented and may be more physiologically relevant. 
Here we show that ALS/FTD-causing mutations in the LCD of the SG protein TIA1 
significantly alter biophysical properties of the protein, strengthening its intermolecular 
interactions and enhancing its propensity to undergo phase transition. In cells, this 
perturbation of TIA1 results in poorly dynamic SGs that fail to appropriately disassemble 
and persist in the cytoplasm long after the removal of stress. We suggest that the 
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accumulation of poorly dynamic SGs (and perhaps other membrane-less organelles that are 
composed of TIA1) create an environment where aggregation-prone molecules that are in 
high concentration (such as TDP-43) have an increased risk of gradually accumulating in an 
insoluble form (Neumann et al., 2006). Whereas TDP-43 forms detergent-resistant 
aggregates, TIA1 fibrils are labile and reversible, thus it is uncertain whether one would 
expect TIA1 or related SG markers to persist as components of the fully mature TDP-43-
positive inclusions that are present at the end-stage of the human disease process. Although 
we found no evidence for such colocalization in post-mortem material from TIA1 mutation 
carriers, prior studies have provided conflicting evidence as to whether or not TIA1 and 
other SG proteins colocalize with the TDP-43 pathology in cases of ALS and FTD in 
general (Aulas and Vande Velde, 2015). Importantly, the impact of ALS/FTD-associated 
TIA1 mutations on SG dynamics mirrors the recent observation that toxic, arginine-
containing poly-dipeptides produced by mutant C9orf72 also disturb phase transitions 
mediated by LCDs and disturb the dynamics of membrane-less organelles, including SGs 
(Lee et al., 2016). This discovery adds to the increasing evidence of a common pathogenic 
mechanism amongst ALS, FTD, and myopathy caused by mutations in RNA-binding 
proteins related to disturbed dynamics of membrane-less organelles, and adds TIA1 to the 
growing list of genes responsible for multisystem proteinopathies; a group of inherited 
pleiotropic degenerative disorders that can variably affect the nervous system, muscle, and 
bone (Taylor, 2015).
STAR Methods
CONTACT FOR REAGENT AND RESOURCE SHARING
For further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contact, Rosa Rademakers (rademakers.rosa@mayo.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Study Populations—One ALS/FTD family (UBCU2) and an ALS case-control 
association cohort were included in this study. All individuals agreed to be in the study and 
biological samples were obtained after informed consent from subjects and/or their proxies. 
UBCU2 is a multigenerational family of Irish/German and other European ancestry, with a 
family history of ALS and ALS with dementia. The proband (UBCU2-1) developed 
progressive limb weakness and hyper-reflexia at age 51, followed by a change in personality 
and behavior at age 54. She died at age 55 with a clinical diagnosis of ALS with early 
behavioral variant frontotemporal dementia (bvFTD). A niece of the proband (UBCU2-14) 
presented with childhood dyslexia and developed changes in personality and expressive 
aphasia at age 28, followed by bulbar and limb weakness a few months later. She suffered 
severe deterioration in language and cognition and progressive weakness during the final 
year and died at age 30 with a clinical diagnosis of FTD with probable ALS. The sister of 
the proband (UBCU2-2) displayed mild memory problems when assessed at age 56.
For the genetic association studies, we analyzed DNA samples of 1039 unrelated ALS 
patients (584 male, 455 female) available in our laboratory, including 38 with a diagnosis of 
FTD in addition to ALS (20 male, 18 female). All patients were of self-reported non-
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Hispanic white ancestry. The average age at diagnosis was 60.0 ± 11.7 years (range 19–88). 
A positive family history of ALS in a first or second degree relative was reported in 136 
patients (13.1%). Patients underwent a full neurological evaluation including 
electromyography, clinical laboratory testing, and imaging as appropriate to establish the 
clinical diagnosis of ALS and were recruited from eight centers: Mayo Clinic Jacksonville 
(n = 612), University of British Columbia, Canada (n = 171), University of Pittsburgh 
School of Medicine (n = 71), Coriell Institute for Medical Research (n = 75), University of 
Chicago Medicine (n = 57), Drexel University College of Medicine (n = 28), Northwestern 
University Feinberg School of Medicine (n = 10), University of Toronto, Canada (n = 11), 
and the University of Western Ontario, Canada (n = 4). Patients with ALS±FTD were 
compared to a group of 3036 controls free of neurodegenerative disease (1442 male, 1594 
female) for genetic association studies. The mean age at blood draw for controls was 64.0 
± 15.3 years (range 20–99). All controls were of non-Hispanic white ancestry ascertained at 
Mayo Clinic Jacksonville (n = 1071), Mayo Clinic Rochester (n = 1738; of which 959 from 
the Mayo Clinic Biobank) and Mayo Clinic Scottsdale (n = 227). All patients signed 
informed consent and this study was approved by the ethics committee of all respective 
institutions.
Mammalian Cell Culture—HeLa cells (of female origin) were grown and maintained in 
DMEM High Glucose (Hyclone SH30022.01) medium supplemented with 10% fetal bovine 
serum. Cells were passaged and plated using 1X TrypLE Express (Thermo Fisher 
Scientific). Cells were authenticated by short tandem repeat (STR) profiling.
Bacterial Cell Culture—cDNA clones were transformed into One Shot TOP10 
chemically competent E. coli (Thermo Fisher Scientific). Single colonies were grown 
overnight at 37°C in LB media containing selection antibiotic at a concentration of 50 μg/ml. 
Cells were pelleted by centrifugation and lysed for harvesting DNA. All competent bacterial 
cells [One Shot TOP10 and BL21(DE3) SOLOS] were stored at −80°C until transformation 
for cloning and recombinant protein expression.
METHOD DETAILS
Whole Exome Sequencing and Variant Calling—Paired-end indexed libraries were 
prepared using the Agilent Bravo liquid handler following the manufacturer’s protocol 
(Agilent Technologies). Briefly, 1 μg of genomic DNA (gDNA) was fragmented using the 
Covaris E210 Sonicator. The settings of duty cycle 10%, intensity 5, cycles 200, time 360 
seconds generated double-stranded DNA fragments with blunt or sticky ends with a 
fragment size mode of 150–200bp. The ends were repaired and phosphorylated using 
Klenow, T4 polymerase, and T4 polynucleotide kinase, after which an “A” base was added 
to the 3′ ends of double-stranded DNA using Klenow exo- (3′ to 5′ exo minus). Paired-end 
Index DNA adaptors (Agilent) with a single “T” base overhang at the 3′ end were ligated, 
and the resulting constructs were purified using AMPure SPRI beads from Agencourt 
(Beckman Coulter Genomics). The adapter-modified DNA fragments were enriched by 4 
cycles of polymerase chain reaction (PCR) using SureSelect forward and SureSelect Pre-
Capture indexing reverse (Agilent) primers. The concentration and size distribution of the 
libraries was determined via Agilent Bioanalyzer DNA 1000 chip.
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Whole exome capture of 75Mb was carried out using the Agilent Bravo liquid handler 
following the protocol for Agilent’s SureSelect XT Human Exome + UTR v5. 750 ng of the 
prepped library was incubated with whole exon biotinylated RNA capture baits supplied in 
the kit for 24 hours at 65°C. The captured DNA:RNA hybrids were recovered using 
Dynabeads MyOne Streptavidin T1 (Life Technologies). The DNA was eluted from the 
beads and purified using Ampure XP (Beckman Coulter Genomics). The purified capture 
products were then amplified using the SureSelect Post-Capture indexing forward and index 
PCR reverse primers (Agilent) for 12 cycles. Libraries were validated and quantified on the 
Agilent Bioanalyzer.
Libraries were pooled at equimolar concentrations in batches of three samples and loaded 
onto paired end flow cells at concentrations of 11 pM to generate cluster densities of 
600,000–800,000/mm2 following Illumina’s standard protocol using the Illumina cBot and 
HiSeq paired-end cluster kit version 3 (Illumina). The flow cells were sequenced as 101 × 2 
paired end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and 
HiSeq data collection version 2.0.12 software. Base-calling was performed using Illumina’s 
RTA version 1.17.21.3. FastQ files were processed into the GENESIS pipeline (Gonzalez et 
al., 2015).
Filtering of Variants—Filtering of variants was performed in the GENESIS web 
application [Innovative genomic collaboration using the GENESIS (GEM.app) platform] 
(Gonzalez et al., 2015). Variants affecting protein sequence such as splice-site, missense, 
non-sense and frameshift variants were selected when present heterozygous in the two 
affected members of family UBCU2. Furthermore, variants were only retained when both 
were absent from the Exome Variant Server (EVS; http://evs.gs.washington.edu/EVS/) 
population, present two times or less in Exome Aggregation Consortium (ExAC; http://
exac.broadinstitute.org/) and the gene harboring the variant is expressed in brain tissue based 
on the GTEX database (http://www.gtexportal.org/). The remaining 15 variants were 
annotated using ANNOVAR (Wang et al., 2010).
Variant Confirmation and TIA1 Screening—For sequence validation of variants 
identified by exome sequencing, specific primers were designed surrounding each rare 
variant shared by UBCU2-1 and UBCU2-14. DNA fragments were amplified using Apex 
products, purified using the Agencourt Ampure system (Beckman Coulter Genomics), and 
sequenced using Big Dye Terminator V3.1 (Applied Biosystems). Sequencing products were 
then purified with CleanSEQ (Beckman Coulter Genomics) and then run on an ABI3730xl 
Genetic Analyzer (Thermo Fisher Scientific). Sequences were analyzed using Sequencher 
4.8 software (Gene Codes Corporation). TIA1 exons 11, 12 and 13 encoding the prion-like 
domain of TIA1 were sequenced from human gDNA in all 1045 patients from our 
association cohort and in 2077 controls. The remaining 959 controls from the Mayo Clinic 
Biobank were analyzed for coding TIA1 mutations using recently generated whole genome 
sequences generated on the HiSeq × Ten System (HudsonAlpha) and analyzed using our in-
house developed GenomeGPS v4.0 pipeline with BWA-MEM alignment to hg38 reference 
and variant calling using Genome Analysis Toolkit (Broad Institute). CADD scores for TIA1 
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variants identified in the additional ALS/FTD patients were generated using CADD web 
interface (https://cadd.gs.washington.edu/).
Mutagenesis—Mutations for TIA1 were created by using the site-directed mutagenesis kit 
(Agilent). TIA1 wild-type and mutants were subsequently cloned into pEGFP-C1 vector at 
BsrG1 and EcoRI site as a fusion gene without affecting the original reading frame of 
EGFP-C1. All clones were verified by restriction enzyme digestion and sequence analysis.
Immunofluorescence—HeLa cells were seeded on 8-well glass slides (Millipore). Cells 
were transfected 24 h after seeding using FuGene 6 (Promega) with GFP-TIA1-WT, GFP-
TIA1-P362L, GFP-TIA1-A381T, or GFP-TIA1-E384K construct. 48 h post transfection, 
cells were stressed with 500 μM sodium arsenite (Sigma-Aldrich) for 30 min. Cells were 
then fixed with 4% paraformaldehyde (Electron Microscopy Sciences), permeabilized with 
0.5% Triton X-100, and blocked in 3% bovine serum albumin (BSA). Primary antibodies 
used were against C-terminal TDP-43 (12892-1-AP; ProteinTech) and G3BP1 (611127; BD 
Biosciences). For visualization, the appropriate host-specific Alexa Fluor 555 or 647 
(Molecular Probes) secondary antibody was used. Slides were mounted using Prolong Gold 
Antifade Reagent with DAPI (Life Technologies). Images were captured using a Leica TCS 
SP8 STED 3X confocal microscope (Leica Biosystems) with a 63x objective.
Double label immunofluorescence was performed on 5-μm thick sections of formalin-fixed, 
paraffin-embedded post-mortem human spinal cord tissue from cases with TIA1 mutations 
(UBC2-1, UBC2-14, NWU-1 and ALS752-1), ALS/FTD patients without TIA1 mutations 
(N = 2) and a neurologically normal control subject. Tissue sections were heated to 60°C for 
20 min, then immediately deparaffinized and rehydrated. Antigen retrieval was performed in 
citrate buffer (10 mM, pH 6.0, 10 min at 95°C in a water bath). The sections were blocked 
for 1 hr with 5% donkey serum in 0.1% Triton X-100 in TBS. Incubation with various 
combinations of primary antibodies (rat anti-phosphorylated TDP-43 from M. Neumann 
(1:1000) (Neumann et al., 2009) combined with one of three anti-TIA1 antibodies: Santa 
Cruz goat anti-TIA1, 1:300; Santa Cruz rabbit anti-TIA1, 1:300; Proteintech rabbit anti-
TIA1, 1:100) was performed in the same blocking solution overnight at 4°C. The sections 
were then washed, and incubated with appropriate Alexa Fluor- or biotin-conjugated 
secondary antibodies at 1:1000 dilution for 1 hour at room temperature. Were needed, a third 
step with Alexa Fluor-conjugated streptavidin (1:1000) was added for 40 min. Background 
fluorescence was then quenched by staining with 0.1% Sudan Black in 70% ethanol for 15 
min. Slides were mounted after 15 minute incubation in DAPI with Prolong-Gold anti-fade 
reagent (Invitrogen). Microscopy was performed using a Nikon Eclipse i-80 epifluorescent 
microscope and NIS-Elements software. Images were further processed and merged using 
Image J.
Live-Cell Time-Lapse Imaging and Fluorescence Recovery After 
Photobleaching—HeLa cells (ATCC) were seeded on sterilized 40mm #1.5 thick 
coverslips (Bioptechs Inc.). Cells were transfected 24 h after seeding using FuGene 6 
(Promega) with 0.5 μg GFP-TIA-1-WT, GFP-TIA1-P362L, GFP-TIA1-A381T, GFP-TIA1-
E384K, or wild type TDP-43-TdTOMATO construct. 48 hours post transfection, the 
coverslip was transferred to a FCS2 chamber, assembled according to the manufacturer’s 
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instructions (Bioptechs Inc.). Media was perfused through the chamber, and then the 
chamber was placed into a Marianas Spinning Disk Confocal system with a stage-top 
incubator and 63× objective with an objective heater (Bioptechs Inc.), both preheated to 
37°C. The Microaqueduct Slide heater (part of the FCS2 system) was set to 37°C, and the 
heated objective with 37°C immersion oil (Zeiss) was raised until it immersed the coverslip, 
and the system was left to equilibrate for 10 minutes after both the Microaqueduct Slide and 
objective heaters read 37°C.
For time-lapse imaging, using SlideBook software with definite focus engaged, multipoint 
images were taken every 20 seconds with the 488 nm laser at 30% power. Two minutes into 
imaging, both the Microaqueduct Slide and Objective temperatures were raised to 43°C to 
begin heat shock. 30 min later, both were lowered back to 37°C to alleviate the stress and 
were imaged until granules disappeared or after 3–4 hours passed. 250–500 μL fresh media 
was perfused through the chamber at every hour of imaging.
For fluorescence recovery after photobleaching, using SlideBook software with continuous 
definite focus engaged, images were taken every 500 milliseconds with the 561 nm laser at 
15% power for 87.5 seconds. 5 frames into imaging cytoplasmic regions were 
photobleached at 50% 561nm FRAP laserstack power for 1ms. The microaqueduct slide and 
objective heaters were raised to 43°C to induce str ess granules and the stress granules were 
photobleached under the same conditions as the cytoplasmic regions prior to stress. 
Recovery curves were normalized to background fluorescence for subtracting noise, and 
adjacent non-bleached cells for fluorescence intensity fluctuations. Half recovery time and 
mobile fraction at the end of 87.5 seconds were empirically calculated. Average and 
standard errors were calculated from fifteen individual traces for cytoplasmic regions before 
heat shock, and sixteen individual traces after heat shock.
Recombinant TIA1 Cloning and Purification—Purification of TIA1 was followed as 
given in Lee et al. (Lee et al., 2016). Recombinant DNA for TIA1 wild-type, E384K, P362L 
and A381T constructs were cloned into pETite N-His SUMO Kan vector (Lucigen 
Corporation). Plasmids were chemically transformed into BL21_DE3 cells (Lucigen 
Corporation). A single bacterial colony, from a Luria-Broth (LB) agar plate with 600 μg/ml 
of kanamycin was grown overnight at 37°C, in 50 mL LB medium with 600 μg/ml of 
Kanamycin (LB-Kan), shaking at 200 rpm (New Brunswick Innova 44R shaker). Saturated 
overnight culture was transformed into two 2.5 L baffled flasks, each of 1 L LB medium 
with Kanamycin. Cell density, measured by OD600, was allowed to reach 0.5 by shaking at 
37°C. After inducing with 500 μM isopropyl β-D-1-thiogalactopyranoside (IPTG), 
expression was done for 20 h at 16°C.
Cells were pelleted at 4000 × g for 20 min at 4°C. Pellets from 1 L of cell culture were 
resuspended and solubilized in 50 ml of 50 mM HEPES, pH 7.5, 2 mM DTT, 250 mM NaCl 
buffer with cOmplete, Mini, EDTA-free protease inhibitor cocktail (Sigma-Aldrich). 
Resuspended cells were lysed by passing through a LM10 microfluidizer (Microfluidics) at 
18,000 psi. Cell debris were pelleted at 17,000 × g at 4°C for 1 h and the supernatant was 
decanted and filtered through a 0.45 micron PVDF membrane. Supernatant was loaded onto 
a HisTrap FF Ni-column (GE Healthcare), washed with lysis buffer, and eluted with 300 
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mM imidazole. The proteins were treated with 0.2 mg/ml RNase A (Roche) for 15 min at 
37°C. His-SUMO-TIA1, with a calculated isoelectric point of 6.5, was purified by ion 
exchange chromatography with a HiTrap Q column (GE Healthcare) using a salt gradient 
from 75 mM to 500 mM NaCl. The fractions were analyzed by SDS-PAGE gel, pooled, and 
concentrated. They were then subjected to size exclusion chromatography on a Superdex 
200 16/60 column (GE Healthcare) equilibrated in 50 mM HEPES, pH 7.5, 400 mM NaCl, 
and 5 mM dithiothreitol (DTT). The fractions were analyzed by SDS-PAGE gel, pooled, 
concentrated, and stored at −80°C. Absence of RNA was confirmed by TBE Urea gel 
electrophoresis and 260/280 absorbance ratio. Proteins were labelled with Oregon Green and 
Texas Red using Molecular Probes Protein Labeling Kits.
Phase Separation—Protocol from Elbaum-Garfinkle et al. (Elbaum-Garfinkle et al., 
2015) was modified to obtain the phase diagram (also known as co-existence line of T 
versus concentration of dilute phase) of TIA1 variants. Purified proteins were diluted to 15 
μM, 150 mM NaCl with 50 mM HEPES at pH 7.5. Dilution of salt from 400 mM NaCl 
(storage buffer) to 150 mM NaCl induced phase separation. Samples were filtered through a 
0.22 micron PVDF membrane to get rid of aggregates, and incubated at six different 
temperatures (5, 10, 15, 20, 25 and 30°C) for 30 min. After equilibration at six different 
temperatures, samples were centrifuged at their respective temperatures at 21,000 × g for 7 
min. Experiments were performed in six replicates for wild-type and P362L, and thrice for 
A381T and E384K to obtain the average and standard error of the mean (S.E.M.). Curves 
were fit to data using a quadratic equation (R2 wild-type=0.99; R2 P362L=0.99; R2 
A381T=0.97; R2 E384K=0.99). Light or protein-depleted phase was decanted, and 
concentration was measured using a NanoDrop at 280 nm with molar extinction coefficient 
of His-SUMO-TIA1 calculated as 82195 M-1 cm-1 (Wilkins et al., 1999). Standardization 
of protein concentration with respect to A280 was confirmed by SDS-PAGE. See also Figure 
S3.
In Vitro Fibrillization—Fibrillization was monitored by Thioflavin T (ThT) fluorescence 
at 480 nm. Filtered, phase separated samples of 20 μM of proteins and 5 μM ThT at 50 mM 
HEPES, pH 7.5, 5 mM DTT, 150 mM NaCl, were observed with a 100x oil objective 
through Leica SP8 confocal microscope. Kinetics of fibrillization was studied on a 96-well 
plate reader using filtered light phase (2.5 μM protein concentration) at room temperature. 
Samples were agitated on an Eppendorf Thermomixer C heat block at 300 rpm for 24 h. ThT 
fluorescence at 480 nm was observed at 0 h (defined as sample immediately after filtration), 
2, 5, 8 and 24 h. Baseline correction was performed using 2.5 μM BSA as a standard 
solution. Experiments were performed in six replicates for wild-type and P362L, and thrice 
for A381T and E384K to obtain average and S.E.M.
For transmission electron microscopy (TEM), reaction mixture (10 μl) of TIA1 wild-type or 
mutants, after 2 h agitation at 300 rpm of 20 μM proteins, was directly deposited on a 
surface of a TEM grid (CF-400-Cu; Electron Microscopy Sciences). The surface of the grid 
was washed three times with 10 μl of distilled water. The grid was subsequently stained for a 
few seconds with a 10 μl drop of 2% uranyl acetate. After the uranyl acetate solution was 
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blotted, the grid was dried in air. TEM images were obtained with a JEOL 1200EX electron 
microscope at 120 kV.
Fluorescence Recovery After Photobleaching in Droplets—Droplets of 25 μM 
protein samples (spiked with Oregon Green for wild-type, or Texas Red for P362L, A381T 
and E384K variants at a ratio of 1:1000 labeled to unlabeled protein) were observed on a 
Linkam PE100 thermal stage (at 20°C) mounted on a Marianas spinning disk confocal 
imaging system on a Zeiss Axio Observer inverted microscope platform. Droplets were 
photobleached using 70% FRAP laserstack power for 5 ms. Images were obtained every 300 
ms to observe fluorescence recovery up to 225 s. Recovery curves were normalized to 
background fluorescence for subtracting noise, and adjacent non-bleached droplet for 
fluorescence intensity fluctuations. Half recovery time and mobile fraction at the end of 225 
s were empirically calculated. Average and standard errors were calculated from six 
individual traces for wild-type and A381T, eight for P362L, and ten for E384K. All imaging 
were done on hydrophobic coverslips (HybriSlip; Molecular Probes) sandwiching Secure-
Seal Imaging Spacers (0.12 mm depth).
Human Tissue Solubility Assay—Urea fractions were prepared from human frontal 
cortex tissue as described previously with few modifications (Neumann et al., 2007; Zhang 
et al., 2007). Approximately 100 mg of brain tissue was homogenized in 500 μl Tris-
buffered saline (TBS) and centrifuged at 25,000 × g for 30 min at 4°C. Pellets were re-
homogenized in 500 μl TBS and re-centrifuged under the same conditions. Pellets were 
resuspended in TBS containing 1% Triton X-100 (TX buffer) and centrifuged at 180,000 × g 
for 30 min at 4°C. Pelle ts were again suspended in TX buffer supplemented with 30% 
sucrose and centrifuged at 180,000 × g for 30 min at 4°C. Pellets were re-homogenized in a 
1% sarkosyl solution, after which samples rotated at room temperature for 1 hr. Samples 
were then centrifuged at 180,000 × g for 30 min at room temperature before re-extracting 
the remaining pellet in 50 03BCl of 7M urea. All buffers, with the exception of urea, were 
supplemented with protease and phosphatase inhibitors. Urea-extracted samples were stored 
at −80°C until use.
Cell Culture Solubility Assay—Solubility and biochemical analysis was performed as 
described in Kim HJ et al., Nature 2013 with several modifications. For each sample ~3 × 
106 cells were washed twice with ice-cold 1x PBS and lysed in ice-cold RIPA buffer (25 
mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS; 
ThermoFisher 89900). Cell lysates were then passed through a 21□gauge needle 10 times 
before being cleared by centrifugation at 100,000 × g for 30 min at 4°C to generate RIPA-
soluble fraction. The pellets were washed twice with ice cold RIPA buffer and re-centrifuged 
for 10 min. RIPA-insoluble pellets were then extracted with urea buffer (7 M urea, 2 M 
thiourea, 4% CHAPS, 30 mM Tris, pH 8.5) by vortexing samples for 15 sec every 10 min 
for 30 min while at room temperature. The samples were then centrifuged at 100,000 g for 
30 min at 4°C. Halt Protease and Phosphatase Inhibi tor (ThermoFisher # 78443) was added 
to all buffers before use. Proteins were resolved by NuPAGE Novex 4–12% Bis-Tris Gel 
(Invitrogen).
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Western Blotting—For human urea fractions, an equal volume of sample and Tris-glycine 
Novex buffer (Life Technologies; supplemented with 5% β-mercaptoethanol) were prepared 
for Western blotting and were not further denatured. Samples were loaded into SDS 
polyacrylamide gels (Life Technologies) and electrophoresis was run at 80V. Protein was 
transferred onto an Immobilon PVDF membrane (Millipore) at 230 mA for 4 hrs. 
Membranes were blocked for 1 hr in 5% dehydrated milk (prepared in TBS containing 
0.05% Tween-20) before incubation with primary antibody. Horseradish peroxidase-
conjugated secondary antibody (Promega) incubation followed by enhanced 
chemiluminescence was used for the detection of proteins. Primary antibodies used were 
goat anti-TIA1 (1:2,000; Santa Cruz), phosphorylated TDP-43 (1:1000), and rabbit anti-
TDP-43 (1:10,000; ProteinTech).
Histology—Human tissues were stained with hematoxylin and eosin (HE), HE combined 
with Luxol fast blue (HE/LFB) and Bielschowsky silver method.
Immunohistochemistry (IHC)—Standard IHC was performed on 5-μm thick human 
tissue sections using the Ventana BenchMark XT automated staining system (Ventana) and 
developed with aminoethylcarbizole (AEC). The primary antibodies employed were as 
follows: ubiquitin (DAKO; 1:500 following microwave antigen retrieval), p62 Lck ligand 
(BD Biosciences; 1:500 following microwave antigen retrieval), TDP-43 (ProteinTech; 
1:1,000 following microwave antigen retrieval), hyperphosphorylated tau (clone AT-8; 
Innogenetics, Ghent, Belgium; 1:2,000 following microwave antigen retrieval), α-synuclein 
(Thermo Scientific; 1:10,000 following microwave antigen retrieval), anti-beta amyloid (Aβ; 
DAKO; 1:100 with initial incubation for 3 h at room temperature), and FUS (Sigma-Aldrich; 
1:200, initial overnight incubation at room temperature, following microwave antigen 
retrieval).
IHC was also performed on sections of spinal cord and frontal cortex from TIA1 mutation 
carriers, sporadic ALS patients in whom TIA1 mutations were excluded, and normal control 
subjects using a number of commercial antibodies raised against various N-terminal and C-
terminal epitopes of human TIA1, including: ProteinTech TIA1 (rabbit polyclonal against aa 
1–214: 1:50, overnight incubation following microwave antigen retrieval), Santa Cruz 
TIA-1/TIAR (clone H-120; rabbit polyclonal against aa 21–140; 1:200, overnight incubation 
following microwave antigen retrieval), Santa Cruz TIA-1/TIAR (clone D-9; mouse 
monoclonal against aa 21–140; 1:200, overnight incubation following microwave antigen 
retrieval), Santa Cruz TIA1 (clone C-20; goat polyclonal raised against the TIA1 C-
terminus; 1:5000 following steaming antigen retrieval in sodium citrate buffer, pH 6), 
Abcam TIA1 ab40693 (rabbit polyclonal antibody raised against aa 350-C-terminus; 1:500 
following microwave antigen retrieval), Abcam TIA1 ab140595 (rabbit monoclonal antibody 
against aa 350-C-terminus; 1:100, overnight incubation) and Beckman Coulter TIA1 
(IM2550; mouse monoclonal raised against human leukemia cells; 1:400 following heat 
retrieval).
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QUANTIFICATION AND STATISTICAL ANALYSIS
Genetic Statistical Analyses—Gene-based analyses were performed using the SNP-set 
(Sequence) Kernel Association Test (SKAT) R package using variants with minor allele 
frequency < 0.0001 and adjusted for age and gender (Wu et al., 2011). We only tested TIA1 
and only rare variants in the LCD were included in the analysis based on the specific 
mutation identified by exome sequencing in family UBCU2 and prior functional evidence 
implicating LCDs of other RNA binding proteins in ALS-FTD. The 8.7×10−6 p-value 
associated with rare TIA1 LCD mutations is just short of exome-wide significance 
(p=2.5×10−6).
Live-Cell Analysis—Live-cell imaging analysis was done manually, determining when 
granules appeared and disappeared for each cell. Only viable cells which were not rounded 
and which did not have spontaneous granules (puncta present prior to the 2 minute mark in 
the video) were considered. For these cells, all of which being considered granule negative at 
the beginning of the video, were considered granule positive upon the frame at which 
distinct cytoplasmic puncta were visible. The frame at which no cytoplasmic puncta were 
visible any longer was when the cells were once again considered granule negative. Images 
were analyzed using SlideBook software. For n=24, 8, 19, and 8 videos for wild-type, 
P362L, A381T, and E384K, respectively, the percent of cells which were considered granule 
positive was determined and graphed at each time point. Two-way ANOVA with Dunnett’s 
multiple comparisons test was performed using GraphPad Prism v6. A p-value of less than 
0.05 was used to determine significance.
Automated Image Analysis—The same live-cell videos were subjected to automated 
puncta detection analysis using CellProfiler software (Broad Institute of Harvard and MIT). 
Individual frames of all movies were exported as tiff images and imported into the 
CellProfiler where each frame was individually analyzed. An automated analysis pipeline 
consisted of applying a “speckle” enhancement step prior to thresholding. A speckle is an 
area of enhanced intensity relative to its immediate neighborhood. The module enhances 
speckles using a white tophat filter with a feature size of 10 pixels. After the speckle 
enhancement the granules were detected by applying adaptive “Robust Background” 
thresholding method. Adaptive strategy partitions the input image into tiles of 30 pixels and 
calculates thresholds for each tile. For each tile, the calculated threshold is applied only to 
the pixels within that tile. This approach is well suited for cells with varying intensity in the 
same movie (field of view). The Robust Background thresholding method applied within the 
tiles assumes that the background distribution approximates a Gaussian and trims the 
brightest and dimmest 5% of pixel intensities. It then calculates the mean and standard 
deviation of the remaining pixels and calculates the threshold as the mean + 3 times the 
standard deviation. Following the thresholding step all detected puncta were separated based 
on intensity and shape variation. Finally, the number and area of all segmented puncta 
objects were calculated and exported for making the graphs of the number and the average 
of area of SGs versus time using Microsoft Excel and/or Igor Pro (Wavemetrics). All graphs 
were normalized to maximum values. The purpose of these graphs is to show the behavior of 
the sample response to heat shock and supports our manual observation and analysis (Figure 
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2B). The fluorescence signal from each cell type was compared for one selected frame 
(Figure S2C) when cells had significant number of mature SGs.
Phase Diagram, Fibrillization, and FRAP Analyses—Statistical analyses were 
performed using GraphPad Prism v6 or Microsoft Office Excel. All data are shown as the 
mean ± standard error of the mean (SEM). The statistical significance of each variant 
compared to wild-type TIA1 was investigated by Pearson correlation coefficient (Pearson’s 
chi-square test), ordinary one-way ANOVA followed by Dunnett’s multiple comparisons 
test, or two-way ANOVA followed by Dunnett’s multiple comparisons test. The number of 
samples analyzed per experiment is provided in the corresponding figure legends. A p-value 
of less than 0.05 was used to determine significance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TIA1 Mutations Identified in Family UBCU2 and Patients with ALS or ALS/FTD
(A) Abbreviated pedigree of the UBCU2 family of European ancestry included in this study 
showing unaffected individuals (white), individuals diagnosed with ALS or ALS/FTD 
(black) and an individual with early memory problems (gray). The proband is denoted with 
an arrow. Two family members with pathological diagnosis of ALS and FTLD-TDP were 
examined by whole-exome sequencing (*). Sanger sequencing confirmed the TIA1 P362L 
mutation in III-1, III-2 and IV-14, the only family members with DNA available. (B) TIA1 
gene organization and protein structure with conserved regions of the TIA1 LCD. Mutations 
identified in this study are numbered and marked in red in relation to the known E384K 
mutation identified in Welander distal myopathy (blue). (C) Images of autopsy pathology 
from patient UBCU2-1 showing TDP-43-immunoreactive neuronal cytoplasmic inclusions 
in the frontal cortex (i) and hyaline Lewy body-like cytoplasmic inclusions in lower motor 
neurons, demonstrated with H&E stain (ii, arrowhead) and TDP-43 immunohistochemistry 
(iii). See also Figure S1, Table S1, Table S2, and Table S3.
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Figure 2. Phase Separation and Mobility of TIA1 is Altered by Disease-Causing Mutations
(A) Schematic representation showing PONDR score along the length of wild-type TIA1, 
the location of the LCD, and the positions of disease-causing missense mutations P362L, 
A381T, and E384K. (B) Temperature-sensitive, reversible phase separation of wild-type 
TIA1 was observed by DIC microscopy. BSA protein was used as a negative control. (C) 
Phase diagrams [temperature (T) versus concentration] showing co-existence lines of wild-
type, P362L, A381T, and E384K TIA1 (150 mM NaCl, pH 7.5 in absence of any co-
solutes). Insets represent characteristic DIC images of single-phase (upper left) and two-
phase (lower right) solutions of wild-type TIA1. n = 6 for wild-type and P362L, n = 3 for 
A381T and E384K; P < 0.001 for each variant compared to wild-type by Pearson’s chi-
square test. (D) Disease-causing mutations P362L, A381T, and E384K reduce the mobility 
of TIA1 in the dense phase. Fluorescence images of wild-type or mutant TIA1 droplets 0–
225 seconds after photobleaching within the region outlined in yellow (arrow). (E) TIA1 
fluorescence recovery after photobleaching in the dense phase indicates a significant 
reduction in mobility (n = 10 for E384K; n = 8 for P362L; n = 6 for wild-type and A381T). 
Recovery curves were normalized to background fluorescence (for subtracting noise) and 
adjacent non-bleached droplet (for fluorescence intensity fluctuations). P < 0.001 for each 
variant compared to wild-type by Pearson’s chi-square test. (F) Quantification of the half 
fluorescence recovery time and mobile fraction of wild-type and mutant TIA1. All graphs 
represent mean ± S.E.M. *P < 0.05, ***P < 0.001 by one-way ANOVA with Dunnett’s 
multiple comparisons test. Scale bars: 20 μm (B) and 10 μm (D). See also Figure S2.
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Figure 3. Live-cell Imaging Illustrates Prolongation of SG Recovery in Association with Disease-
Causing TIA1 Mutations
(A) Images of HeLa cells transfected with GFP-tagged wild-type or mutant (P362L, A381T, 
or E384K) TIA1. SGs were induced with a 30-minute heat shock at 43°C (shaded in orange) 
and images were taken 0–120 min after recovery at 37°C. (B) Line graph representing the 
percentage of cells with visible TIA1 puncta over time (n = 24, 8, 19, and 8 videos for wild-
type, P362L, A381T, and E384K, respectively). (C) Quantification of the percentage of cells 
with persistent SGs at 120 min. *P < 0.05, **P < 0.01, ***P < 0.001 by two-way ANOVA 
with Dunnett’s multiple comparisons test. Scale bar: 10 μm. See also Figure S3, Figure S4, 
and Video File.
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Figure 4. TDP-43 is Recruited to TIA1-positive Stress Granules and TDP-43 Becomes Insoluble 
in Response to Stress
(A) Immunofluorescence confocal microscopy shows intracellular colocalization of 
endogenous TDP-43 (using an antibody targeting the C-terminus) with TIA1-positive stress 
granules of all four variants. GFP-tagged TIA1 constructs were transiently transfected in 
HeLa cells and cells were stressed with sodium arsenite for 30 min. Cells were fixed and 
stained with DAPI (blue), TDP-43 (red), and G3BP (far red), another marker of stress 
granules. Scale bar: 10 μm. (B) FRAP of TDP-43-TdTomato in HeLa cells (outlined in 
white) shows that cytoplasmic TDP-43 in resting cells (preHS, top row) is highly mobile. 
However, after heat shock stress, the TDP-43 that is recruited into SGs becomes immobile 
(middle row), while the TDP-43 that remains in the cytoplasm of the same cells (not in SGs, 
bottom row) remains highly mobile. Scale bar: 10 μm. (C) Quantification of FRAP analysis 
in (B). Pre-bleach: n = 15 cells; Post-bleach: n = 16 cells (SGs) and 23 cells (cytoplasm). (D) 
Prolonged sodium arsenite (Ars) stress promotes insolubility of TDP-43. Sequential 
extractions of U2OS cells under the following conditions: control (Ctl), 30 min Ars, and 30 
min Ars + 3 hrs recovery (RE), 1 hr Ars, 1 hr Ars + 3 hrs RE, shows that TDP-43 
accumulates in the urea-soluble fraction in response to stress. (E) Quantification of RIPA 
and urea-soluble blots in (D) shows TDP-43 can recover from the urea-soluble to the RIPA-
soluble fraction after a 30-min stress but not after a 1-hr stress. n = 3 biological replicates. 
All graphs represent mean ± S.E.M. ***P < 0.001 by one-way ANOVA with Dunnett’s 
multiple comparisons test. n.s., not significant. See also Figure S4.
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